… Board (SAB). In vivo proof of concept data for novel Axiomer ® RNA editing platform technology presented at the … 1/2 trial of QR-110, announcing the in vivo PoC for our Axiomer technology and the completion of the pre-clinical … programs and our novel RNA-editing technology, Axiomer ® . We are also thrilled with the spin out of Amylon …
… transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced … please contact your Chardan representative. About Axiomer ® ProQR is pioneering a next-generation RNA base …
Annual General Meeting of Shareholders to be held on June 30, 2022René Beukema joins management team as Chief Corporate Development Officer and General Counsel and is nominated to Management BoardGerard Platenburg to assume Chief Scientific Officer role, with le
Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022
Positive data reported from the Phase 1/2 clinical trial of QR-421a for the treatment of Usher syndrome and non-syndromic retini
LEIDEN, the Netherlands, May 23, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the appointment of Dr.